Patients with spinal muscular atrophy treated with a one-time infusion of onasemnogene abeparvovec-xioi continue to show clinically meaningful benefits even 5 years after dosing.
Researchers explored the incidence, clinical characteristics, associated factors, and clinical outcomes of late cerebrovascular events >30- days after TAVR.
The study compared improvements in frontal lobe dysfunction induced by rTMS and improvement of white matter integrity revealed by diffusion tensor imaging in patients with TRD receiving rTMS treatment.
Predictors of all-cause hospitalizations in patients with MS included increased age, presence of a comorbidity, and having a history of hospital admissions.
Biohaven announced positive topline results from a pivotal phase 2/3 study evaluating rimegepant for the preventive treatment of episodic and chronic migraine in adults.
Physiologic traits that cause obstructive sleep apnea are also associated with adherence to continuous positive airway pressure in patients with stroke.
